HRP20191163T1 - Heteroaromatski spojevi i njihova upotreba kao dopaminskih liganda d1 - Google Patents

Heteroaromatski spojevi i njihova upotreba kao dopaminskih liganda d1 Download PDF

Info

Publication number
HRP20191163T1
HRP20191163T1 HRP20191163TT HRP20191163T HRP20191163T1 HR P20191163 T1 HRP20191163 T1 HR P20191163T1 HR P20191163T T HRP20191163T T HR P20191163TT HR P20191163 T HRP20191163 T HR P20191163T HR P20191163 T1 HRP20191163 T1 HR P20191163T1
Authority
HR
Croatia
Prior art keywords
alkyl
cycloalkyl
group
haloalkyl
alkoxy
Prior art date
Application number
HRP20191163TT
Other languages
English (en)
Inventor
Michael Aaron Brodney
Jennifer Elizabeth Davoren
Amy Beth Dounay
Ivan Viktorovich Efremov
David Lawrence Firman Gray
Michael Eric GREEN
Jaclyn Louise HENDERSON
Chewah LEE
Scot Richard MENTE
Steven Victor O'neil
Bruce Nelsen Rogers
Lei Zhang
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51205521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20191163(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HRP20191163T1 publication Critical patent/HRP20191163T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Claims (22)

1. Spoj Formule I: , ili njegova farmaceutski prihvatljiva sol, naznačen time što: svakog od T1, T2, T3 i T4 se neovisno bira iz skupine koju čine H, halogen, -CN, -SF5, -OH, -N(Ra)(Rb), -C(=O)-N(Ra)(Rb), -C(=O)-ORc, -C(=O)-Rd, C1-6 alkil, C1-6 halogenalkil, C2-6 alkenil, C2-6 alkinil, C1-6 alkoksi, C1-6 halogenalkoksi, -S-(C1-6 alkil), C3-7 cikloalkil, 4- do 7-eročlani heterocikloalkil, C3-7 cikloalkoksi, 5- ili 6-eročlani heteroaril, ciklopropilmetil, te ciklobutilmetil, gdje svaki od C1-6 alkil, C2-6 alkenil, C2-6 alkinil, -S-(C1-6 alkil), te C1-6 alkoksi može biti supstituiran s jednim ili više supstituenata, od kojih se svakog neovisno bira iz skupine koju čine halogen, -OH, -CN, -N(Ra)(Rb), C1-4 alkoksi, C1-4 halogenalkoksi, te -S-(C1-4 alkil); te gdje svaki od C3-7 cikloalkil, 4- do 7-eročlani heterocikloalkil, C3-7 cikloalkoksi, 5- ili 6-eročlani heteroaril, ciklopropilmetil, te ciklobutilmetil u T1, T2, i T3 može biti supstituiran s jednim ili više supstituenata, od kojih se svakog neovisno bira iz skupine koju čine halogen, -OH, -CN, okso, -N(Ra)(Rb), -C(=O)OH, -C(=O)-C1-4 alkil, -C(=O)-O-C1-4 alkil, -C(=O)-N(Ra)(Rb), C1-4 alkil, C1-4 halogenalkil, C1-4 hidroksilalkil, C1-4 cijanoalkil, C1-4 alkoksi, C1-4 halogenalkoksi, te -S-(C1-4 alkil); L1 se bira iz skupine koju čine O i S; svakog od Ra i Rb se neovisno bira iz skupine koju čine H, C1-4 alkil, C3-7 cikloalkil, te ciklopropilmetil; ili Ra i Rb zajedno s N atomom na kojeg su vezani tvore 4- do 7-eročlani heterocikloalkil, koji može biti supstituiran s jednim ili više supstituenata, od kojih se svakog neovisno bira iz skupine koju čine halogen, -OH, -CN, okso, -NH2, -NH(C1-4 alkil), -N(C1-4 alkil)2, -C(=O)OH, -C(=O)-C1-4 alkil, -C(=O)-O-C1-4 alkil, -C(=O)-NH2, -C(=O)-NH(C1-4 alkil), - C(=O)-N(C1-4 alkil)2, C1-4 alkil, C1-4 halogenalkil, C1-4 hidroksilalkil, C1-4 cijanoalkil, C1-4 alkoksi, -S-(C1-4 alkil), te C1-4 halogenalkoksi; svaki od Rc i Rd je neovisno C1-4 alkil, C3-4 cikloalkil-C1-2 alkil-, ili C3-4 cikloalkil; Q1 je Q1b: , uz uvjet da je atom ugljika u prstenu Q1 vezan na benzenski prsten Formule I; svaki od X1 i X2 je neovisno O ili S; svaki od R1, R2, R3 i R4 se neovisno bira iz skupine koju čine H, halogen, -OH, -NO2, -CN, -SF5, C1-6 alkil, C1-6 halogenalkil, C1-6 halogenalkoksi, C2-6 alkenil, C2-6 alkinil, C3-7 cikloalkil, 4- do 10-eročlani heterocikloalkil, -N(R5)(R6), -N(R7)(C(=O)R8), -C(=O)-N(R5)(R6), -C(=O)-R8, -C(=O)-OR8, -N(R7)(S(=O)2R8), -S(=O)2N(R5)(R6), -SR8, te -OR8, gdje svaki od C1-6 alkil, C3-7 cikloalkil, i heterocikloalkil može biti supstituiran s 1, 2 ili 3 supstituenta, od kojih se svakog neovisno bira iz skupine koju čine halogen, -CN, okso, -OH, C1-4 alkil, C1-4 alkoksi, C1-4 halogenalkil, C1-4 halogenalkoksi, C3-6 cikloalkil, -N(R5)(R6), -N(R7)(C(=O)R8), -C(=O)-OR8, -C(=O)H, -C(=O)R8, -C(=O)N(R5)(R6), -N(R7)(S(=O)2R8), -S(=O)2-N(R5)(R6), -SR8, te -OR8; ili R2 i R4 zajedno s dva atoma ugljika na koje su vezani tvore kondenzirani 5- ili 6-eročlani heteroaril, kondenzirani 5- ili 6-eročlani heterocikloalkilni prsten, kondenzirani 5- ili 6-eročlani cikloalkilni prsten, ili kondenzirani benzenski prsten, gdje svaki od kondenziranih prstena može biti supstituiran s 1, 2 ili 3 supstituenta, od kojih se svakog neovisno bira iz skupine koju čine halogen, -CN, -OH, C1-4 alkil, C1-4 alkoksi, C1-4 halogenalkil, te C1-4 halogenalkoksi, te gdje kondenzirani heterocikloalkilni prsten ili kondenzirani cikloalkilni prsten može biti dodatno supstituiran s 1, 2 ili 3 okso; R5 je H, C1-4 alkil, C1-4 halogenalkil ili C3-7 cikloalkil; R6 je H ili se bira iz skupine koju čine C1-4 alkil, C1-4 halogenalkil, C3-7 cikloalkil, 4- do 10-eročlani heterocikloalkil, C6-10 aril, 5- do 10-eročlani heteroaril, (C3-7 cikloalkil)-C1-4 alkil-, (4- do 10-eročlani heterocikloalkil)-C1-4 alkil-, (C6-10 aril)-C1-4 alkil-, te (5- do 10-eročlani heteroaril)-C1-4 alkil-, gdje svaki od odabira iz skupine može biti supstituiran s 1, 2, 3 ili 4 supstituenta, od kojih se svakog neovisno bira iz skupine koju čine -OH, -CN, C1-4 alkil, C3-7 cikloalkil, C1-4 hidroksilalkil, -S-C1-4 alkil, -C(=O)H, -C(=O)-C1-4 alkil, -C(=O)-O-C1-4 alkil, -C(=O)-NH2, -C(=O)-N(C1-4 alkil)2, C1-4 halogenalkil, C1-4 alkoksi, te C1-4 halogenalkoksi; ili R5 i R6 zajedno s N atomom na kojeg su vezani tvore 4- do 10-eročlani heterocikloalkil ili 5- do 10-eročlani heteroaril, od kojih svaki može biti supstituiran s 1, 2, 3, 4 ili 5 supstituenata, od kojih se svakog neovisno bira iz skupine koju čine halogen, -OH, okso, -C(=O)H, -C(=O)-C1-4 alkil, -C(=O)OH, -C(=O)-OC1-4 alkil, -C(=O)-NH2, -C(=O)-N(C1-4 alkil)2, -CN, C1-4 alkil, C1-4 alkoksi, C1-4 hidroksilalkil, C1-4 halogenalkil, te C1-4 halogenalkoksi; R7 se bira iz skupine koju čine H, C1-4 alkil, te C3-7 cikloalkil; R8 se bira iz skupine koju čine C1-6 alkil, C3-7 cikloalkil, 4- do 10-eročlani heterocikloalkil, C6-10 aril, 5- do 10-eročlani heteroaril, (C3-7 cikloalkil)-C1-4 alkil-, (4- do 10-eročlani heterocikloalkil)-C1-4 alkil-, (C6-10 aril)-C1-4 alkil-, te (5- do 10-eročlani heteroaril)-C1-4 alkil-, gdje svaki od odabira iz skupine može biti supstituiran s 1, 2 ili 3 supstituenta, od kojih se svakog neovisno bira iz skupine koju čine halogen, -CF3, -CN, -OH, okso, -S-C1-4 alkil, C1-4 alkil, C1-4 halogenalkil, C2-6 alkenil, C2-6 alkinil, C3-7 cikloalkil, C1-4 alkoksi, te C1-4 halogenalkoksi; R10 se bira iz skupine koju čine halogen, -OH, -CN, -SF5, -NO2, C1-6 alkil, C1-6 halogenalkil, C1-6 hidroksilalkil, C1-6 alkoksi, C1-6 halogenalkoksi, C3-7 cikloalkil, C2-6 alkenil, C2-6 alkinil, C6-10 aril, 4- do 10-eročlani heterocikloalkil, 5- do 10-eročlani heteroaril, (C3-7 cikloalkil)-C1-4 alkil-, (4- do 10-eročlani heterocikloalkil)-C1-4 alkil-, (C6-10 aril)-C1-4 alkil-, (5- do 10-eročlani heteroaril)-C1-4 alkil-, -N(R5)(R6), -N(R7)(C(=O)R8), -S(=O)2N(R5)(R6), -C(=O)-N(R5)(R6), -C(=O)-R8, -C(=O)-OR8, -SR8, te -OR8, gdje svaki od C1-6 alkil, C3-7 cikloalkil, C6-10 aril, 4- do 10-eročlani heterocikloalkil, 5- do 10-eročlani heteroaril, (C3-7 cikloalkil)-C1-4 alkil-, (4- do 10-eročlani heterocikloalkil)-C1-4 alkil-, (C6-10 aril)-C1-4 alkil-, te (5- do 10-eročlani heteroaril)-C1-4 alkil- može biti supstituiran s 1, 2, 3 ili 4 supstituenta, od kojih se svakog neovisno bira iz skupine koju čine halogen, -OH, -CN, -NO2, C1-4 alkil, C1-4 hidroksilalkil, C1-4 alkoksi, -N(R5)(R6), -S-(C1-4 alkil), -S(=O)2-(C1-4 alkil), C6-10 ariloksi, [(C6-10 aril)-C1-4 alkiloksi- koji može biti supstituiran s 1 ili 2 C1-4 alkil], okso, -C(=O)H, -C(=O)-C1-4 alkil, -C(=O)O-C1-4 alkil, -C(=O)NH2, -NHC(=O)H, -NHC(=O)-(C1-4 alkil), C3-7 cikloalkil, a 5- ili 6-eročlani heteroaril, C1-4 halogenalkil, te C1-4 halogenalkoksi; R10A se bira iz skupine koju čine H, C1-6 alkil, C1-6 hidroksilalkil, C2-6 alkenil, -S(=O)2N(R5)(R6), -C(=O)-N(R5)(R6), -C(=O)-R8, -C(=O)-OR8, -SR15, -C(R14)2-OH, -C(R14)2-OS(=O)2H, -C(R14)2-OP(=O)(OH)2, -C(R14)2-OR15, -C(R14)2-OC(=O)-R15, -C(R14)2-N(R5)(R6); R10B se bira iz skupine koju čine H, C1-6 alkil, C1-6 halogenalkil, C1-6 hidroksilalkil, C3-7 cikloalkil, C3-6 alkenil, C3-6 alkinil, C6-10 aril, 4- do 10-eročlani heterocikloalkil, 5- do 10-eročlani heteroaril, (C3-7 cikloalkil)-C1-4 alkil-, (4- do 10-eročlani heterocikloalkil)-C1-4 alkil-, (C6-10 aril)-C1-4 alkil-, (5- do 10-eročlani heteroaril)-C1-4 alkil-, -S(=O)2N(R5)(R6), -C(=O)-N(R5)(R6), -C(=O)-R8, i -C(=O)-OR8, gdje svaki od C1-6 alkil, C3-7 cikloalkil, C6-10 aril, 4- do 10-eročlani heterocikloalkil, 5- do 10-eročlani heteroaril, (C3-7 cikloalkil)-C1-4 alkil-, (4- do 10-eročlani heterocikloalkil)-C1-4 alkil-, (C6-10 aril)-C1-4 alkil-, te (5- do 10-eročlani heteroaril)-C1-4 alkil-, može biti supstituiran s 1, 2, 3 ili 4 supstituenta, od kojih se svakog neovisno bira iz skupine koju čine halogen, -OH, -CN, -NO2, C1-4 alkil, C1-4 hidroksilalkil, C1-4 alkoksi, -N(R5)(R6), -S-(C1-4 alkil), -S(=O)2-(C1-4 alkil), C6-10 ariloksi, [(C6-10 aril)-C1-4 alkiloksi- koji može biti supstituiran s 1 ili 2 C1-4 alkil], okso, -C(=O)H, -C(=O)-C1-4 alkil, -C(=O)O-C1-4 alkil, -C(=O)NH2, -NHC(=O)H, -NHC(=O)-(C1-4 alkil), -OC(=O)-C1-4 alkil, C3-7 cikloalkil, a 5- ili 6-eročlani heteroaril, C1-4 halogenalkil, te C1-4 halogenalkoksi; svaki R14 je neovisno H ili se bira iz skupine koju čine C1-10 alkil, C3-14 cikloalkil, C2-10 alkenil, C2-10 alkinil, C6-10 aril, 4- do 10-eročlani heterocikloalkil, 5- do 10-eročlani heteroaril, (C3-14 cikloalkil)-C1-10 alkil-, (4- do 14-eročlani heterocikloalkil)-C1-10 alkil-, (C6-10 aril)-C1-10 alkil-, (5- do 10-eročlani heteroaril)-C1-10 alkil-, gdje svaki od odabira između skupina može biti supstituiran s 1, 2, 3 ili 4 supstituenta, od kojih se svakog neovisno bira iz skupine koju čine halogen, -OH, -CN, -NO2, C1-4 alkil, C1-4 hidroksilalkil, C1-4 alkoksi, -N(R5)(R6), -N(R7)C(=O)R8, -N(R7)C(=O)OR8, -N(R7)S(=O)2R8, -S(=O)2N(R5)(R6), -C(=O)-N(R5)(R6), -C(=O)-R8, -C(=O)-OR8, -SR8, -OR8, -S(=O)2-R8, C6-10 ariloksi, [(C6-10 aril)-C1-4 alkiloksi-koji može biti supstituiran s 1 ili 2 C1-4 alkil], okso, -C(=O)H, -NHC(=O)H, C3-7 cikloalkil, a 5- ili 6-eročlani heteroaril, C1-4 halogenalkil, te C1-4 halogenalkoksi; R15 se bira iz skupine koju čine C1-20 alkil, C3-14 cikloalkil, C2-20 alkenil, C2-20 alkinil, C6-10 aril, 4- do 14-eročlani heterocikloalkil, 5- do 10-eročlani heteroaril, (C3-14 cikloalkil)-C1-20 alkil-, (4- do 10-eročlani heterocikloalkil)-C1-20 alkil-, (C6-10 aril)-C1-20 alkil-, (5- do 10-eročlani heteroaril)-C1-20 alkil-, gdje svaki od odabira između skupina može biti supstituiran s 1, 2, 3 ili 4 supstituenta, od kojih se svakog neovisno bira iz skupine koju čine halogen, -OH, -CN, -NO2, C1-4 alkil, C1-4 hidroksilalkil, C1-4 alkoksi, -N(R5)(R6), -N(R7)C(=O)R8, -N(R7)C(=O)OR8, -N(R7)S(=O)2R8, -S(=O)2N(R5)(R6), -C(=O)-N(R5)(R6), -C(=O)-R8, -C(=O)-OR8, -SR8, -OR8, -S(=O)2-R8, C6-10 ariloksi, [(C6-10 aril)-C1-4 alkiloksi- koji može biti supstituiran s 1 ili 2 C1-4 alkil], okso, -C(=O)H, -NHC(=O)H, C3-7 cikloalkil, a 5- ili 6-eročlani heteroaril, C1-4 halogenalkil, te C1-4 halogenalkoksi; i t2 je 0 ili 1.
2. Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, naznačen time što je spoj Formule I spoj Formule IB-1, IB-2, IB-3, IB-4 ili IB-5, IB-6, IB-7, IB-8, IB-9 ili IB-10:
3. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 ili 2, ili njegova farmaceutski prihvatljiva sol, naznačen time što: R10 se bira iz skupine koju čine -CN, C1-4 alkil, C3-4 cikloalkil, ciklopropilmetil, te ciklobutilmetil, gdje C1-4 alkil u R10 može biti supstituiran s 1, 2, 3 ili 4 supstituenta, od kojih se svakog neovisno bira iz skupine koju čine halogen, -OH, -CN, C1-4 alkoksi, te C1-4 halogenalkoksi; te gdje svaki od C3-4 cikloalkila, ciklopropilmetila, te ciklobutilmetila u R10 može biti supstituiran s 1, 2, 3 ili 4 supstituenta, od kojih se svakog neovisno bira iz skupine koju čine halogen, -OH, -CN, C1-4 alkil, C1-4 halogenalkil, C1-4 hidroksilalkil, C1-4 alkoksi, te C1-4 halogenalkoksi; R10A se bira iz skupine koju čine H, C1-3 alkil, C1-3 hidroksilalkil, C2-4 alkenil, -S(=O)2N(R5)(R6), -C(=O)-N(R5)(R6), -C(=O)-R8, -C(=O)-OR8, -C(R14)2-OH, -C(R14)2-OS(=O)2H, -C(R14)2-OP(=O)(OH)2, -C(R14)2-OR15, te -C(R14)2-OC(=O)-R15; i R10B se bira iz skupine koju čine C1-4 alkil, C3-4 cikloalkil, ciklopropilmetil, te ciklobutilmetil, gdje C1-4 alkil u R10B može biti supstituiran s 1, 2, 3 ili 4 supstituenta, od kojih se svakog neovisno bira iz skupine koju čine halogen, -OH, -CN, C1-4 alkoksi, te C1-4 halogenalkoksi; te gdje svaki od C3-4 cikloalkila, ciklopropilmetila, te ciklobutilmetila u R10B može biti supstituiran s 1, 2, 3 ili 4 supstituenta, od kojih se svakog neovisno bira iz skupine koju čine halogen, -OH, -CN, C1-4 alkil, C1-4 halogenalkil, C1-4 hidroksilalkil, C1-4 alkoksi, te C1-4 halogenalkoksi.
4. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, ili njegova farmaceutski prihvatljiva sol, naznačen time što se svakog od R10 i R10B neovisno bira iz skupine koju čine C1-3 alkil, C1-3 halogenalkil, te ciklopropil.
5. Spoj u skladu s bilo kojim od patentnih zahtjeva patentnim zahtjevom 1 do 4, ili njegova farmaceutski prihvatljiva sol, naznačen time što je svaki od R10 i R10B neovisno metil ili etil.
6. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 5, ili njegova farmaceutski prihvatljiva sol, naznačen time što se svakog od R1 i R2 neovisno bira iz skupine koju čine H, halogen, -CN, C1-6 alkil, C1-6 halogenalkil, C1-6 alkoksi, C1-6 halogenalkoksi, C3-6 cikloalkil, -C(=O)-(C1-4 alkil), te C(=O)-O-(C1-4 alkil), gdje svaki od C1-6 alkil i C3-6 cikloalkil može biti supstituiran s 1, 2 ili 3 supstituenta, od kojih se svakog neovisno bira između halogena, -OH, -CN, C1-4 alkil, C1-4 halogenalkila, C1-4 alkoksi, te C1-4 halogenalkoksi.
7. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, ili njegova farmaceutski prihvatljiva sol, naznačen time što je svaki od R1 i R2 neovisno H, metil ili halogen.
8. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7, ili njegova farmaceutski prihvatljiva sol, naznačen time što je svaki od R1 i R2 H.
9. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 8, ili njegova farmaceutski prihvatljiva sol, naznačen time što se svakog od R3 i R4 neovisno bira iz skupine koju čine H, halogen, -CN, - C1-4 alkil, C1-4 alkoksi, te C3-4 cikloalkil, gdje svaki od C1-4 alkil i C1-4 alkoksi u R3 i R4 može biti supstituiran s 1, 2 ili 3 supstituenta, od kojih se svakog neovisno bira između halogena, -OH, C1-4 alkoksi, te C1-4 halogenalkoksi; te gdje C3-4 cikloalkil u R3 i R4 može biti supstituiran s 1, 2 ili 3 supstituenta, od kojih se svakog neovisno bira između halogena, -OH, C1-4 alkila, C1-4 halogenalkila, C1-4 alkoksi, te C1-4 halogenalkoksi.
10. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 9, ili njegova farmaceutski prihvatljiva sol, naznačen time što je R3 H; a R4 je H, halogen, ili metil, gdje metil može biti supstituiran s 1, 2 ili 3 supstituenta, od kojih se svakog neovisno bira iz skupine koju čine halogen, -OH, te C1-4 alkoksi.
11. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 10, ili njegova farmaceutski prihvatljiva sol, naznačen time što je R3 H, a R4 je metil.
12. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 11, ili njegova farmaceutski prihvatljiva sol, naznačen time što se svakog od T1, T2, T3 i T4 neovisno bira iz skupine koju čine H, halogen, -CN, C1-4 alkil, C1-4 halogenalkil, C2-4 alkenil, C1-4 alkoksi, C1-4 halogenalkoksi, te C3-4 cikloalkil, gdje svaki od C1-4 alkila, C2-4 alkenila, te C1-4 alkoksi u T1, T2, T3 i T4 može biti supstituiran s jednim ili više supstituenata, od kojih se svakog neovisno bira iz skupine koju čine halogen, -OH, -CN, C1-4 alkoksi, te C1-4 halogenalkoksi; te gdje C3-4 cikloalkil u T1, T2, T3 i T4 može biti supstituiran s jednim ili više supstituenata, od kojih se svakog neovisno bira iz skupine koju čine halogen, -OH, -CN, C1-4 alkil, C1-4 halogenalkil, C1-4 hidroksilalkil, C1-4 cijanoalkil, C1-4 alkoksi, te C1-4 halogenalkoksi.
13. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 12, ili njegova farmaceutski prihvatljiva sol, naznačen time što se svakog od T1, T2, T3 i T4 neovisno bira iz skupine koju čine H, halogen, C1-4 alkil, C1-4 hidroksilalkil, C1-4 halogenalkil, C1-4 alkoksi, C1-4 halogenalkoksi, C3-4 cikloalkil, te C3-4 halogencikloalkil.
14. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 13, ili njegova farmaceutski prihvatljiva sol, naznačen time što se T1 bira iz skupine koju čine halogen, ciklopropil, halogenciklopropil, metil, C1 halogenalkil, metoksi, te C1 halogenalkoksi; a T4 je H.
15. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je (–)-6-{4-[(3-ciklopropilpiridin-2-il)oksi]-2-metilfenil}-1,5-dimetilpirimidin-2,4(1H,3H)-dion, ili njegova farmaceutski prihvatljiva sol.
16. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je (–)-6-{4-[(3-klor-5-fluorpiridin-2-il)oksi]-2-metilfenil}-1,5-dimetilpirimidin-2,4(1H,3H)-dion, ili njegova farmaceutski prihvatljiva sol.
17. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je 6-{4-[(3-klorpiridin-2-il)oksi]-2-metilfenil}-5-etil-1-metilpirimidin-2,4(1H,3H)-dion, ili njegova farmaceutski prihvatljiva sol.
18. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je (–)-1,5-dimetil-6-(2-metil-4-{[3-(trifluormetil) piridin-2-il]oksi}fenil)pirimidin-2,4(1H,3H)-dion, ili njegova farmaceutski prihvatljiva sol.
19. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je (–)-6-{4-[(3-klor-5-metilpiridin-2-il)oksi]-2-metilfenil}-1,5-dimetilpirimidin-2,4(1H,3H)-dion, ili njegova farmaceutski prihvatljiva sol.
20. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 19, ili njegovu farmaceutski prihvatljivu sol, kao i farmaceutski prihvatljivu podlogu.
21. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 19, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju poremećaja kojeg se bira između shizofrenije, kognitivnog poremećaja, poremećaja nedostatka pažnje uz hiperaktivnost (ADHD), impulzivnosti, kompulzivnog kockanja, prekomjernog jedenja, poremećaja iz spektra autizma, blagog kognitivnog poremećaja (MCI), staračkog slabljenja kognitivnih funkcija, demencije, sindroma nemirnih nogu (RLS), Parkinsonove bolesti, Huntingtonove koreje, anksioznosti, depresije, velikog depresivnog poremećaja (MDD), depresije otporne na liječenje (TRD), bipolarnmog poremećaja, kronične apatije, anhedonije, kroničnog umora, posttraumatskog stresnog poremećaja, sezsonskog afektivnog poremećaja, poremećaja socijalne anksioznosti, postpartalne depresija, serotoninskog sindroma, zloupotrebe tvari i ovisnosti o narkoticima, recidiva zloupotrebe narkotika, Touretteovog sindroma, tardivne diskinezije, pospanosti, prekomjerne pospanosti po danu, kaheksjie, nedostatka pažnje, spolne disfunkcije, migrene, sistemnog eritematoznog lupusa (SLE), hiperglikemije, ateroskleroze, dislipidemije, pretilosti, dijabetesa, sepse, postishemijeske tubularne nekroze, bubrežne insuficijencije, hiponatriemije, resistentnog edema, narkolepsje, hipertenzije, kongestivne srčane insuficijencije, postoperativne okularne hipotonije, poremećaja spavanja, te boli.
22. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 21, naznačen time što se poremećaj bira između shizofrenije, kognitivnog poremećaja, blagog kognitivnog poremećaja (MCI), staračkog slabljenja kognitivnih funkcija, demencije, te Parkinsonove bolesti.
HRP20191163TT 2013-06-27 2019-06-27 Heteroaromatski spojevi i njihova upotreba kao dopaminskih liganda d1 HRP20191163T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361840144P 2013-06-27 2013-06-27
PCT/IB2014/062217 WO2014207601A1 (en) 2013-06-27 2014-06-13 Heteroaromatic compounds and their use as dopamine d1 ligands
EP14739554.5A EP3013813B1 (en) 2013-06-27 2014-06-13 Heteroaromatic compounds and their use as dopamine d1 ligands

Publications (1)

Publication Number Publication Date
HRP20191163T1 true HRP20191163T1 (hr) 2019-10-04

Family

ID=51205521

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20230546TT HRP20230546T1 (hr) 2013-06-27 2014-06-13 Heteroaromatski spojevi i njihova upotreba kao dopaminskih d1 liganada
HRP20191163TT HRP20191163T1 (hr) 2013-06-27 2019-06-27 Heteroaromatski spojevi i njihova upotreba kao dopaminskih liganda d1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20230546TT HRP20230546T1 (hr) 2013-06-27 2014-06-13 Heteroaromatski spojevi i njihova upotreba kao dopaminskih d1 liganada

Country Status (42)

Country Link
US (10) US9527831B2 (hr)
EP (2) EP3421462B1 (hr)
JP (1) JP6026024B2 (hr)
KR (1) KR101781723B1 (hr)
CN (1) CN105324376B (hr)
AP (1) AP2015008844A0 (hr)
AR (1) AR096748A1 (hr)
AU (1) AU2014300673B2 (hr)
BR (1) BR122023004130B1 (hr)
CA (1) CA2916653C (hr)
CL (1) CL2015003735A1 (hr)
CR (1) CR20150634A (hr)
CU (1) CU24334B1 (hr)
DK (2) DK3421462T3 (hr)
DO (1) DOP2015000302A (hr)
EA (1) EA028637B1 (hr)
EC (1) ECSP16003103A (hr)
ES (2) ES2948192T3 (hr)
FI (1) FI3421462T3 (hr)
GT (1) GT201500350A (hr)
HK (1) HK1215435A1 (hr)
HR (2) HRP20230546T1 (hr)
HU (2) HUE062265T2 (hr)
IL (1) IL242480B (hr)
MA (1) MA38661A1 (hr)
MD (1) MD20150122A2 (hr)
MX (2) MX2015017169A (hr)
NI (1) NI201500179A (hr)
NZ (1) NZ713762A (hr)
PE (1) PE20160664A1 (hr)
PH (1) PH12015502502A1 (hr)
PL (2) PL3421462T3 (hr)
PT (2) PT3421462T (hr)
RS (2) RS64342B1 (hr)
SG (1) SG11201509186TA (hr)
TN (1) TN2015000547A1 (hr)
TR (1) TR201907981T4 (hr)
TW (1) TWI508957B (hr)
UA (1) UA112945C2 (hr)
UY (1) UY35628A (hr)
WO (1) WO2014207601A1 (hr)
ZA (1) ZA201508252B (hr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3323821A1 (en) 2012-11-08 2018-05-23 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
WO2014207601A1 (en) 2013-06-27 2014-12-31 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
EP3134405B1 (en) 2014-04-25 2019-08-28 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
BR112016023740A2 (pt) 2014-04-25 2017-08-15 Pfizer compostos heteroaromáticos e seu uso como ligantes de dopamina d1
CA2946471C (en) 2014-04-25 2018-08-07 Pfizer Inc. Fused bicyclic heteroaromatic compounds and their use as dopamine d1 ligands
EP3137469B1 (en) 2014-04-28 2019-10-09 Pfizer Inc Heterocyclic compounds and their use as dopamine d1 ligands
EP3137454A1 (en) 2014-04-28 2017-03-08 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
JOP20150177B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
CN111153859B (zh) * 2015-04-15 2021-09-03 江苏恩华药业股份有限公司 哒嗪酮类衍生物及其应用
BR112018007395A2 (pt) 2015-10-14 2018-10-23 Bristol-Myers Squibb Company 2,4-di-hidróxi-nicotinamidas como agonistas de apj
ES2820823T3 (es) 2015-12-18 2021-04-22 Janssen Pharmaceutica Nv Ligandos PET mGluR2/3 radiomarcados
AU2016374571B2 (en) 2015-12-18 2021-05-06 Janssen Pharmaceutica Nv Radiolabelled mGluR2/3 PET ligands
ES2837018T3 (es) * 2016-01-15 2021-06-29 Pfizer Ligandos del receptor D3 de dopamina de 6,7,8,9-tetrahidro-5H-pirido[2,3-d]azepina
BR112018068341A2 (pt) 2016-03-24 2019-01-15 Bristol-Myers Squibb Company 6-hidróxi-4-oxo-1,4-di-hidropirimidina-5-carboxamidas como agonistas de apj
CN108884055B (zh) 2016-03-30 2022-07-12 石原产业株式会社 哒嗪酮系化合物或其盐、以及含有它们的除草剂
WO2018157843A1 (zh) * 2017-03-02 2018-09-07 中国科学院上海药物研究所 2-(取代苯杂基)芳香甲酸类fto抑制剂，其制备方法及其应用
JP2023522949A (ja) * 2020-04-23 2023-06-01 オプナ バイオ ソシエテ アノニム Ｃｄ７３調節のための化合物及び方法並びにそれらの表示
EP4441039A1 (en) 2021-12-03 2024-10-09 Teva Czech Industries s.r.o Solid state forms of tavapadon and processes for preparation thereof
WO2023143321A1 (zh) * 2022-01-29 2023-08-03 苏州科睿思制药有限公司 他伐帕敦的晶型及其制备方法和用途

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5025142B1 (hr) 1969-07-30 1975-08-21
JPS5039272B1 (hr) 1970-07-14 1975-12-16
JPS5025142A (hr) 1973-07-06 1975-03-17
JPS5039272A (hr) 1973-08-10 1975-04-11
JPS5516432B2 (hr) 1974-05-28 1980-05-01
JPS51113899A (en) 1975-03-27 1976-10-07 Yoshitomi Pharmaceut Ind Ltd Method for preparing novel tetrazole derivatives
JPS522031A (en) 1975-06-24 1977-01-08 Japan Niyuupureito Hokushiyou Sunshade device
DE2861615D1 (en) 1978-01-02 1982-03-11 Ciba Geigy Ag Phenoxy-alkyl oxazolines, their preparation, compositions containing them and their application as herbicides
EP0101662A3 (de) 1982-06-25 1985-12-04 Ciba-Geigy Ag Benzoylparabansäuren
US4550108A (en) 1983-08-17 1985-10-29 Ciba Geigy Corporation 1,3,5-Oxadiazine-2,4-diones and pesticidal use
US4723015A (en) 1983-10-17 1988-02-02 Ciba-Geigy Corporation Certain insecticidal N-2-pyridyloxyphenylbenzimidates
IL73611A0 (en) 1983-12-06 1985-02-28 Nippon Soda Co 1,2,4-oxa-and thiadiazolin-3-one derivatives,their preparation and their use as insecticides and fungicides
JPS61275271A (ja) 1985-05-30 1986-12-05 Nippon Soda Co Ltd １，２，４−オキサ（チア）ジアゾリン誘導体、その製造方法，殺虫剤及び農園芸用殺菌剤
DE3545569A1 (de) 1985-12-21 1987-06-25 Hoechst Ag Neue pyridin-derivate, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als schaedlingsbekaempfungsmittel
DE3545786A1 (de) 1985-12-21 1987-06-25 Schering Ag Pyrazolinderivate, ihre herstellung und ihre verwendung als mittel mit insektizider wirkung
DE3631511A1 (de) 1986-09-12 1988-03-24 Schering Ag 5-halogen-1,2,4-triazole, verfahren zu ihrer herstellung und ihre verwendung als akarizide und insektizide mittel
EP0296518A1 (de) 1987-06-22 1988-12-28 Ciba-Geigy Ag Neue Phenylether-derivate als Mikrobizide, Verfahren zu deren Herstellung und deren Verwendung
DE3826855A1 (de) * 1988-08-06 1990-02-15 Cassella Ag 4,5-dihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und ihre verwendung
JPH0259574A (ja) 1988-08-23 1990-02-28 Mitsubishi Kasei Corp ピラジノン誘導体又はその塩類
JPH0259573A (ja) 1988-08-23 1990-02-28 Mitsubishi Kasei Corp ２（１ｈ）−ピリミジノン誘導体又はその塩類
US5066667A (en) 1989-06-26 1991-11-19 Ciba-Geigy Corporation Thioxotetrazolines and insecticidal use thereof
DE69104071T2 (de) 1990-01-18 1995-05-11 Nissan Chemical Ind Ltd Uracilderivate und Pestizide, die diese als wirksame Stoffe enthalten.
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
JPH03261783A (ja) 1990-03-12 1991-11-21 Suntory Ltd １，２，４―トリアジンジオン化合物及びそれを有効成分とする抗コクシジウム剤
DE4030042A1 (de) 1990-05-17 1991-11-21 Bayer Ag Verwendung von substituierten 1,2,4-triazindionen
JP3018422B2 (ja) 1990-07-27 2000-03-13 日東紡績株式会社 床 材
US5630962A (en) 1990-12-19 1997-05-20 Hoechst Aktiengesellschaft 2-Fluoropyridines, their preparation and their use in liquid crystal mixtures
JPH0539272A (ja) 1991-01-09 1993-02-19 Nissan Chem Ind Ltd ピリミジンジオン誘導体および除草剤
JPH0525142A (ja) 1991-07-12 1993-02-02 Nissan Chem Ind Ltd ウラシル誘導体及び有害生物防除剤
JPH05202031A (ja) 1992-01-28 1993-08-10 Nissan Chem Ind Ltd Ｎ−アミノピリミジンジオン誘導体および除草剤
WO1993018016A1 (en) 1992-03-11 1993-09-16 E.I. Du Pont De Nemours And Company Fungicidal oxazolidinones
US5482951A (en) 1992-05-29 1996-01-09 Kumiai Chemical Industry Co., Ltd. Triazole derivatives as well as insecticide and acaricide
EP0612320A1 (en) 1992-08-31 1994-08-31 Ciba-Geigy Ag 4,5-dicyanoimidazole derivatives and pesticidal compositions containing them
AU673881B2 (en) 1992-12-25 1996-11-28 Nippon Soda Co., Ltd. Heterocyclic derivative and pest control agent
JP3261783B2 (ja) 1993-02-04 2002-03-04 ミノルタ株式会社 光変調素子
JP3682075B2 (ja) 1993-04-16 2005-08-10 クミアイ化学工業株式会社 トリアゾール誘導体及び殺虫、殺ダニ剤
WO1995004724A1 (fr) 1993-08-11 1995-02-16 Nippon Soda Co., Ltd. Derive d'imidazole et son procede de production, et substance anti-nuisibles
JPH0873446A (ja) 1994-04-22 1996-03-19 Nippon Soda Co Ltd ヘテロ環化合物および殺虫・殺ダニ剤
JPH0827120A (ja) 1994-07-08 1996-01-30 Nissan Chem Ind Ltd テトラヒドロピリミジノン誘導体
JPH08217777A (ja) 1995-02-10 1996-08-27 Nippon Nohyaku Co Ltd ２−ピラゾリン−５−オン誘導体及びその中間体並びに除草剤
DE19518681A1 (de) 1995-05-22 1996-11-28 Bayer Ag Verfahren zur Herstellung von 5,6-Dihydro-1,3-oxazinen
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
JPH09291282A (ja) 1996-04-26 1997-11-11 Sumitomo Chem Co Ltd 安定化した液晶材料およびこれを用いた液晶素子
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6355799B1 (en) * 1997-10-27 2002-03-12 Isk Americas Incorporated Substituted benzene compounds, process for their preparation, and herbicidal and defoliant compositions containing them
US6521641B1 (en) 1998-10-08 2003-02-18 Allergan, Inc. Male anti-fertility agents
WO2000024735A1 (en) 1998-10-23 2000-05-04 Dow Agrosciences Llc Insecticidal 1-(substituted pyridyl)-1,2,4-triazoles
GB9903671D0 (en) 1999-02-17 1999-04-14 Cenes Ltd Dopamine D-1 receptor agonist compounds
BR0107662A (pt) 2000-01-18 2002-11-19 Pfizer Prod Inc Antagonistas do fator de liberação de corticotropina
JP3831253B2 (ja) 2000-04-04 2006-10-11 塩野義製薬株式会社 高脂溶性化合物を含有する油性組成物
CA2409762A1 (en) 2000-06-23 2002-01-03 Donald J.P. Pinto Heteroaryl-phenyl substituted factor xa inhibitors
US6476055B1 (en) 2001-03-28 2002-11-05 Nippon Soda Co. Ltd. 5,5-disubstituted thiazolidine derivative pesticides
US7501429B2 (en) 2001-04-11 2009-03-10 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
US20020193403A1 (en) 2001-05-03 2002-12-19 Allergan Sales, Inc. Methods of treating hyperlipidemia
EP1386915A4 (en) 2001-05-09 2004-11-10 Sumitomo Chem Takeda Agro Co AZOLE-LIKE COMPOUNDS, PROCESS FOR THE PREPARATION AND USE OF SAID COMPOUNDS
AR036873A1 (es) 2001-09-07 2004-10-13 Euro Celtique Sa Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento
ES2421511T3 (es) 2001-12-21 2013-09-03 X Ceptor Therapeutics Inc Moduladores de LXR
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
WO2003079986A2 (en) 2002-03-18 2003-10-02 Bristol-Myers Squibb Company Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases
WO2004018410A1 (ja) 2002-08-26 2004-03-04 Nissan Chemical Industries, Ltd. 置換ベンズアニリド化合物及び有害生物防除剤
AU2003276201A1 (en) 2002-11-11 2004-06-03 Bayer Healthcare Ag Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
US20040171075A1 (en) 2002-12-31 2004-09-02 Flynn Daniel L Modulation of protein functionalities
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
US6969744B2 (en) 2003-06-19 2005-11-29 University Of Southern Mississippi Living and quasiliving cationic telechelic polymers quenched by N-substituted pyrrole and methods for their preparation
EA009201B1 (ru) 2003-09-03 2007-12-28 Пфайзер Инк. Фенил - или пиридиламидные соединения в качестве антагонистов простагландина e2
JP4451849B2 (ja) 2003-11-28 2010-04-14 日本曹達株式会社 アリール複素環誘導体および農園芸用殺菌剤および殺虫剤
JP2005272452A (ja) 2004-02-23 2005-10-06 Nissan Chem Ind Ltd 置換ベンズアニリド化合物及び有害生物防除剤
JP2007533723A (ja) 2004-04-20 2007-11-22 ファイザー・プロダクツ・インク α２δリガンドを含む組合せ
WO2005113494A2 (en) 2004-05-07 2005-12-01 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
TW200612827A (en) 2004-08-25 2006-05-01 Sumitomo Chemical Co Insecticide composition
ES2396365T3 (es) * 2005-07-29 2013-02-21 Concert Pharmaceuticals Inc. Nuevos derivados de benzo[D][1,3]-dioxol deuterados como inhibidores de la recaptación de serotonina
US7973060B2 (en) 2005-10-13 2011-07-05 Crystalgenomics, Inc. Fab I inhibitor and process for preparing same
GB0524786D0 (en) 2005-12-05 2006-01-11 Glaxo Group Ltd Compounds
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
CA2641766A1 (en) 2006-02-15 2007-08-23 Abbott Laboratories Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
JP5025142B2 (ja) 2006-02-27 2012-09-12 株式会社東芝 モータ制御装置
BRPI0708731A2 (pt) 2006-03-10 2011-06-07 Ono Pharmaceutical Co derivado heterocìclico nitrogenado, e agente farmacêutico compreendendo o derivado como ingrediente ativo
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
WO2007124546A1 (en) 2006-04-28 2007-11-08 Avexa Limited Integrase inhibitors 3
PT2094663E (pt) 2006-09-21 2011-04-19 Piramal Life Sciences Ltd Derivados de piridina para o tratamento de desordens metabólicas relacionadas com resistência à insulina ou hiperglicemia
EP2256496A3 (en) 2006-09-21 2011-03-16 Piramal Life Sciences Limited Method for identifying compounds that act as insulin-sensitizers
RU2478635C2 (ru) 2006-10-19 2013-04-10 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Гетероарильные соединения, содержащие их композиции и способы лечения с применением этих соединений
EP1916240A1 (en) * 2006-10-25 2008-04-30 Syngeta Participations AG Pyridazine derivatives
DE102007003036A1 (de) 2006-12-20 2008-06-26 Bayer Cropscience Ag Pyrimidinylpyrazole
WO2008094909A2 (en) 2007-01-29 2008-08-07 Xenon Pharmaceuticals Inc. Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
JP2010519267A (ja) 2007-02-22 2010-06-03 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト 新規殺微生物剤
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
AR065622A1 (es) 2007-03-07 2009-06-17 Ortho Mcneil Janssen Pharm Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
CN101294257B (zh) 2007-04-23 2014-06-18 株式会社神户制钢所 焊接热影响部的韧性优异的钢材及其制造方法
JP2009062290A (ja) 2007-09-04 2009-03-26 Takeda Chem Ind Ltd シクロプロパン化合物
EA019085B1 (ru) * 2007-09-14 2014-01-30 Янссен Фармасьютикалз, Инк. 1',3-двузамещенные 4-(арил-х-фенил)-1н-пиридин-2-оны
EP2203426B9 (en) 2007-10-31 2013-02-13 Abbott GmbH & Co. KG Benzenesulfonamide compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US20110071197A1 (en) 2008-04-16 2011-03-24 Peter Nilsson Bis-aryl compounds for use as medicaments
US20110112193A1 (en) 2008-05-14 2011-05-12 Peter Nilsson Bis-aryl compounds for use as medicaments
EP2328586A2 (en) 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
CN102131801B (zh) 2008-06-25 2015-04-08 福拉姆医药股份有限公司 1,2-二取代的杂环化合物
CA2736970A1 (en) * 2008-09-12 2010-03-18 Biolipox Ab Pyrimidinone derivatives for use as medicaments
WO2010064688A1 (ja) 2008-12-03 2010-06-10 日本農薬株式会社 ピリミジン誘導体及び該誘導体を含有する農園芸用殺虫剤並びにその使用方法
WO2010068788A1 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Heterocyclic amides as btk inhibitors
PE20142099A1 (es) 2009-01-12 2014-12-13 Icagen Inc Derivados de sulfonamida
EP2246335A1 (de) 2009-02-17 2010-11-03 Bayer CropScience AG Aminopyrimidinamide als Schädlingsbekämpfungsmittel
AU2011223888B2 (en) * 2010-03-04 2015-07-02 Merck Sharp & Dohme Llc Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders
CA2812043A1 (en) 2010-04-23 2011-10-27 Kineta, Inc. Pyrimidinedione anti-viral compounds
KR20120018236A (ko) 2010-07-23 2012-03-02 현대약품 주식회사 치환된 피리미디닐 유도체 및 이의 제조방법
WO2012020848A1 (en) 2010-08-10 2012-02-16 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US9056832B2 (en) 2010-09-17 2015-06-16 Purdue Pharma L.P. Pyridine compounds and the users thereof
PL2753606T3 (pl) * 2011-09-02 2018-02-28 Purdue Pharma L.P. Pirymidyny jako blokery kanałów sodowych
EP3323821A1 (en) * 2012-11-08 2018-05-23 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
GEP201606598B (en) * 2012-11-08 2017-01-10 Pfizer Heteroaromatic compounds as dopamine d1 ligands
WO2014119770A1 (ja) * 2013-01-30 2014-08-07 住友化学株式会社 ピリダジノン化合物及びそれを含有する除草剤
WO2014207601A1 (en) * 2013-06-27 2014-12-31 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands

Also Published As

Publication number Publication date
ZA201508252B (en) 2019-04-24
HUE062265T2 (hu) 2023-10-28
EP3421462A1 (en) 2019-01-02
US10093655B2 (en) 2018-10-09
PT3421462T (pt) 2023-06-29
EA028637B1 (ru) 2017-12-29
US20150196561A1 (en) 2015-07-16
IL242480A0 (en) 2016-02-01
EP3013813B1 (en) 2019-04-03
IL242480B (en) 2019-09-26
EA201592146A1 (ru) 2016-05-31
US9139561B2 (en) 2015-09-22
PT3013813T (pt) 2019-06-14
AR096748A1 (es) 2016-02-03
ES2948192T3 (es) 2023-09-01
HUE043705T2 (hu) 2019-09-30
NI201500179A (es) 2016-02-11
DK3421462T3 (da) 2023-06-12
TWI508957B (zh) 2015-11-21
US20190367485A1 (en) 2019-12-05
CU24334B1 (es) 2018-04-03
SG11201509186TA (en) 2016-01-28
PL3013813T3 (pl) 2019-10-31
CR20150634A (es) 2016-01-04
TW201512185A (zh) 2015-04-01
CL2015003735A1 (es) 2016-06-24
US9527831B2 (en) 2016-12-27
US10421744B2 (en) 2019-09-24
PE20160664A1 (es) 2016-07-09
JP6026024B2 (ja) 2016-11-16
HRP20230546T1 (hr) 2023-08-04
US9822097B2 (en) 2017-11-21
MD20150122A2 (ro) 2016-05-31
US20150005313A1 (en) 2015-01-01
CA2916653C (en) 2017-07-18
GT201500350A (es) 2017-09-28
RS59018B1 (sr) 2019-08-30
CA2916653A1 (en) 2014-12-31
RS64342B1 (sr) 2023-08-31
BR112015030101A2 (pt) 2017-07-25
UY35628A (es) 2015-01-30
US20170057947A1 (en) 2017-03-02
US20200283407A1 (en) 2020-09-10
CN105324376B (zh) 2017-06-23
NZ713762A (en) 2018-03-23
CN105324376A (zh) 2016-02-10
WO2014207601A1 (en) 2014-12-31
EP3421462B1 (en) 2023-04-05
US20190002439A1 (en) 2019-01-03
HK1215435A1 (zh) 2016-08-26
PH12015502502A1 (en) 2016-02-22
DK3013813T3 (da) 2019-06-03
MA38661A1 (fr) 2017-03-31
MX2020013099A (es) 2022-07-26
EP3013813A1 (en) 2016-05-04
US11964961B2 (en) 2024-04-23
TR201907981T4 (tr) 2019-06-21
ECSP16003103A (es) 2017-08-31
US20180037571A1 (en) 2018-02-08
UA112945C2 (uk) 2016-11-10
JP2016531083A (ja) 2016-10-06
US20210300899A1 (en) 2021-09-30
AU2014300673A1 (en) 2015-11-12
BR122023004130B1 (pt) 2023-12-12
US10696658B2 (en) 2020-06-30
KR101781723B1 (ko) 2017-10-23
DOP2015000302A (es) 2016-02-29
MX2015017169A (es) 2016-04-06
US20240317713A1 (en) 2024-09-26
US11014909B2 (en) 2021-05-25
AP2015008844A0 (en) 2015-11-30
US20150175573A1 (en) 2015-06-25
AU2014300673B2 (en) 2017-12-14
ES2729630T3 (es) 2019-11-05
FI3421462T3 (fi) 2023-06-26
TN2015000547A1 (fr) 2017-04-06
KR20160014665A (ko) 2016-02-11
PL3421462T3 (pl) 2023-09-11
US9107923B2 (en) 2015-08-18
CU20150180A7 (es) 2016-05-30

Similar Documents

Publication Publication Date Title
HRP20191163T1 (hr) Heteroaromatski spojevi i njihova upotreba kao dopaminskih liganda d1
HRP20191469T1 (hr) Novi kondenzirani spojevi piridina kao inhibitori kazeinske kinase
HRP20210526T1 (hr) Oksisteroli i postupci za njihovu uporabu
AU2010339423B9 (en) Therapeutic compounds and related methods of use
FI3932919T3 (fi) Jak-inhibiittoriyhdiste ja sen käyttö
AR108325A1 (es) Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR082885A1 (es) Compuestos y composiciones para la inhibicion de nampt
ES2734735T3 (es) Derivados de 4-oxo-3,4-dihidro-1,2,3,-benzotriazina como moduladores de GPR139
AR053728A1 (es) Pirimidinas condensadas como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia y composiciones farmaceuticas que las contienen en combinacion con otros agentes terapeuticos
AR067027A1 (es) Derivados de 2, 3-dihidro-1h-pirrol[3, 4b]quinolin-1-ona, una composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la modulacion de la actividad del receptor gaba a.
HRP20171031T1 (hr) Supstituirani tetrahidrokarbazol i karbazol karboksamid spojevi koji se koriste kao inhibitori kinaze
PE20130005A1 (es) Compuestos triciclicos novedosos
AR047160A1 (es) Compuestos moduladores de cb1
PE20150399A1 (es) Nuevos derivados de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
JP2017513887A5 (hr)
RU2016137169A (ru) Гетероциклические соединения, способ их получения и их применение
JP2014522837A (ja) 治療用化合物としてのキナゾリン及び関連の使用方法
JP2014503544A5 (hr)
AR059056A1 (es) Heterociclos compo agonistas del receptor de acido nicotinico para el tratamiento de la dislipidemia
RU2009103307A (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ
JP2015528018A5 (hr)
JP2008511574A5 (hr)
JP2016523908A5 (hr)
RU2012106743A (ru) Производные хромонов, способ их получения и их терапевтические применения
HRP20192258T1 (hr) Kv1.3 inhibitori i njihove medicinske primjene